VTV Therapeutics

Overview

VTV Therapeutics (formerly vTv Therapeutics Inc.) is a clinical-stage pharmaceutical company dedicated to developing novel oral small-molecule drugs for the treatment of Alzheimer's disease and other disorders. Founded in 2015 as a spin-off from TransTech Pharma, the company focuses on targeting specific disease pathways to develop disease-modifying therapies through a portfolio approach spanning multiple therapeutic candidates at various stages of development["@vtvcompany"].

Overview

VTV Therapeutics (formerly vTv Therapeutics Inc.) is a clinical-stage pharmaceutical company dedicated to developing novel oral small-molecule drugs for the treatment of Alzheimer's disease and other disorders. Founded in 2015 as a spin-off from TransTech Pharma, the company focuses on targeting specific disease pathways to develop disease-modifying therapies through a portfolio approach spanning multiple therapeutic candidates at various stages of development["@vtvcompany"].

The company's name "VTV" stands for "Vision, Therapeutic Value" reflecting its mission to create meaningful value through innovative pharmaceutical development. VTV became a publicly traded company in 2015, listing on NASDAQ under the ticker VTVT["@secfiling"].

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | High Point, North Carolina, USA |
| Founded | 2015 (spin-off from TransTech Pharma) |
| Ticker | NASDAQ: VTVT |
| Focus Areas | Alzheimer's disease, Metabolic disorders |
| Platform | Small-molecule drug discovery |
| Status | Public (clinical-stage) |

History and Milestones

VTV Therapeutics emerged from TransTech Pharma, a drug discovery company that had been operating since the late 1990s. The spin-off was designed to focus specifically on clinical development of promising therapeutic candidates that had emerged from TransTech's research programs.

Key milestones in the company's history include:

• 2015: Company founded as vTv Therapeutics Inc. following spin-off from TransTech Pharma
• 2015: Initial public offering (IPO) on NASDAQ
• 2016-2018: Advancement of T3MT through Phase 2 clinical trials
• 2017: Strategic collaboration with AstraZeneca on AZD-1981
• 2019: Announcement of T3MT Phase 2 results
• 2020-2021: Pipeline diversification efforts

Technology Platform

VTV Therapeutics employs a structure-based drug design approach combined with high-throughput screening to identify and optimize small-molecule therapeutic candidates. The company's platform focuses on:

Pipeline and Programs

Alzheimer's Disease Programs

T3MT (T3/Trooper)

T3MT was VTV's lead clinical candidate for Alzheimer's disease. This small-molecule agent was designed to modify the course of Alzheimer's disease through a novel mechanism targeting amyloid-beta aggregation and neurotoxicity[@t3mtmechanism].

• Mechanism: T3MT is a small-molecule agent designed to modify the course of Alzheimer's disease through a novel mechanism targeting [amyloid-beta](/proteins/amyloid-beta) aggregation and neurotoxicity. Unlike monoclonal antibody approaches that target existing amyloid plaques, T3MT was designed to prevent the formation of toxic oligomers and aggregates.
• Indication: Alzheimer's disease (mild-to-moderate)
• Status: Completed Phase 2 clinical trials

AZD-1981

VTV collaborated with AstraZeneca on the development of AZD-1981, a novel oral drug candidate for Alzheimer's disease[@azd1981].

• Mechanism: PPAR-delta (peroxisome proliferator-activated receptor delta) agonist. PPAR-delta activation has been shown to have neuroprotective effects in preclinical models of neurodegeneration through multiple mechanisms including improved mitochondrial function, reduced neuroinflammation, and enhanced lipid metabolism in the brain.
• Indication: Alzheimer's disease
• Status: Completed clinical trials (Phase 2)

Other CNS Programs

VTV has maintained early-stage research programs in other CNS disorders, though most have not advanced to clinical development. These programs have included:

• Neuroprotection: Small molecules designed to support neuronal survival under conditions of metabolic stress
• Neuroinflammation: Modulators of microglial activation and inflammatory pathways
• Synaptic function: Compounds aimed at preserving synaptic plasticity and function

Metabolic Programs

VTV has also developed programs in metabolic diseases, reflecting the overlap between metabolic dysfunction and neurodegenerative processes:

• TTP273: A GLP-1 receptor agonist for type 2 diabetes (completed Phase 2 trials). This program leveraged the company's expertise in small-molecule GPCR modulators[@pipeline].
• Metabolic candidates: Early-stage programs in obesity and related conditions
• Type 2 Diabetes: The GLP-1 program represented VTV's entry into metabolic disease, an area with significant overlap with CNS in terms of therapeutic modality requirements

Research Approach

VTV Therapeutics employs a portfolio approach to drug development, advancing multiple programs across various stages of development. The company's strategy includes:

Clinical Development

VTV has conducted multiple clinical trials for its Alzheimer's disease candidates, investigating both safety and efficacy in patient populations. The company's clinical development program has included:

• Phase 1 trials in healthy volunteers to establish safety, tolerability, and pharmacokinetic profiles
• Phase 2 trials in patients with mild-to-moderate Alzheimer's disease to evaluate efficacy signals and optimal dosing
• Biomarker studies to assess drug effects on disease pathology, including amyloid PET imaging, CSF biomarkers, and cognitive endpoints

Strategic Partnerships

VTV has established strategic partnerships with major pharmaceutical companies and academic institutions:

• AstraZeneca: Collaboration on AZD-1981 and other programs. This partnership provided additional resources for clinical development while allowing VTV to maintain commercial rights in certain territories.
• Academic collaborations: Partnerships with academic medical centers for translational research in Alzheimer's disease, including biomarker development and clinical validation studies.
• Contract Research Organizations (CROs): Engagement with specialized CROs for clinical trial execution across multiple sites.

Competitive Landscape

VTV Therapeutics operated in a competitive landscape alongside other companies pursuing Alzheimer's disease therapeutics:

| Company | Approach | Status |
|--------|----------|--------|
| Biogen/Eisai | Aducanumab (anti-amyloid antibody) | Approved (accelerated) |
| Eli Lilly | Donanemab (anti-tau antibody) | Phase 3 |
| Roche | Gantenerumab (anti-amyloid antibody) | Phase 3 |
| VTV Therapeutics | T3MT (small molecule) | Phase 2 |
| AstraZeneca | AZD-1981 (PPAR-delta agonist) | Phase 2 |

VTV's small-molecule approach differentiated it from the dominant monoclonal antibody strategies pursued by larger pharmaceutical companies. Oral bioavailability represented a potential competitive advantage if efficacy were demonstrated.

Financial Overview

As a public company, VTV has been funded through a combination of:

• Initial Public Offering (2015): Raised capital through NASDAQ listing
• Collaborations: Revenue from AstraZeneca and other partnerships
• Research grants: Funding from governmental and foundation sources
• At-the-market (ATM) offerings: Periodic equity sales to fund operations

Relevance to Neurodegeneration Research

VTV Therapeutics represents an important example of a company pursuing alternative therapeutic approaches to Alzheimer's disease beyond amyloid-targeted therapies. Their work on small-molecule modulators of disease pathways provides insights into novel mechanisms being explored in the field:

The company's trajectory also illustrates the challenges facing Alzheimer's disease drug development, where multiple candidates have failed in late-stage clinical trials despite promising preclinical data.

Challenges and Lessons Learned

The Alzheimer's disease drug development landscape has proven extremely challenging, with numerous high-profile failures even in late-stage trials. VTV's experience with T3MT and other candidates reflects several broader lessons:

Future Directions

While VTV's Alzheimer programs have not yet achieved regulatory approval, the company's approach to neurodegeneration drug development has contributed valuable insights to the field. Future directions may include:

• Repurposing opportunities: Exploring whether existing compounds may have utility in other neurological conditions
• Biomarker partnerships: Collaboration on biomarker development for patient stratification
• Acquisition or partnership: Potential acquisition by larger pharmaceutical company seeking to expand neuroscience pipeline

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [PPAR Signaling in Neurodegeneration](/mechanisms/ppar-signaling-neurodegeneration)
• [Small Molecule Therapeutics](/therapeutics/small-molecule-therapies-neurodegeneration)

External Links

• [VTV Therapeutics Official Website](https://www.vtvtreatments.com/)
• [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001566830)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

References